We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

C07-001: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01192399
Recruitment Status : Completed
First Posted : September 1, 2010
Last Update Posted : February 17, 2017
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Brief Summary:
The objective of this study was to assess the safety and efficacy of eculizumab in hemolytic PNH patients. In addition, the pharmacokinetics (PK) and pharmacodynamic (PD) response of eculizumab was assessed and compared to overseas studies of eculizumab treatment in hemolytic PNH patients.

Condition or disease Intervention/treatment Phase
Paroxysmal Nocturnal Hemoglobinuria Biological: Eculizumab Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Study Start Date : November 2007
Primary Completion Date : June 2008
Study Completion Date : October 2008

Arm Intervention/treatment
Experimental: Eculizumab
600 mg of eculizumab as intravenous (IV) infusion once a week for 4 doses, followed by 900 mg eculizumab IV infusion 1 week later for 1 dose, then 900 mg eculizumab IV infusion every 2 weeks for 4 doses.
Biological: Eculizumab
Subjects were treated with open label Eculizumab and following the dose described in the arm/group description.
Other Name: Soliris

Primary Outcome Measures :
  1. Change of LDH [ Time Frame: Baseline to Study Week 12 ]

Secondary Outcome Measures :
  1. Change of total scores of FACIT-Fatigue scale [ Time Frame: Baseline to Study Week 12 ]
  2. Change of PNH RBC count [ Time Frame: Baseline to Study Week 12 ]
  3. Change of number of units of Packed RBCs transfused [ Time Frame: Baseline through study period ]
  4. AUC for change of LDH [ Time Frame: From baseline ]
  5. Change of plasma free hemoglobin [ Time Frame: From baseline to Study Week 12 ]
  6. Change of EORTC QLQ-C30 score [ Time Frame: From baseline to Study Week 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Japanese individuals at least 12 years of age
  • Diagnosis of PNH > 6 months
  • One transfusion in the past two years for anemia or anemia-related symptoms
  • LDH level >/= 1.5 x upper limit of normal within 12 weeks

Exclusion Criteria:

  • Platelet count < 30,000/microliters
  • Known or suspected hereditary complement deficiency
  • History of hematopoietic stem cell transplant
  • History of meningococcal disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01192399

Sponsors and Collaborators
Alexion Pharmaceuticals
Study Director: Stephen Squinto, PhD Alexion Pharmaceuticals

Responsible Party: Alexion Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01192399     History of Changes
Other Study ID Numbers: C07-001
First Posted: September 1, 2010    Key Record Dates
Last Update Posted: February 17, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Alexion Pharmaceuticals:
Hemolytic Paroxysmal Nocturnal Hemoglobinuria

Additional relevant MeSH terms:
Hemoglobinuria, Paroxysmal
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
Anemia, Hemolytic
Hematologic Diseases
Myelodysplastic Syndromes
Bone Marrow Diseases